Highlight
- The RAPID MRI-directed pathway demonstrated high 5-year clinically significant prostate cancer–free survival in men with negative MRI or negative biopsy results.
- Four in ten patients avoided biopsy entirely, with no metastatic spread or cancer-related deaths reported over 5 years.
- Higher PSA density or PI-RADS score did not predict clinically significant cancer in those with prior negative workup.
Background
Prostate cancer diagnosis traditionally relies on systematic biopsy of the gland, often prompted by elevated prostate-specific antigen (PSA) levels or suspicious imaging findings. However, biopsy carries risks—including infection, bleeding, and overtreatment. Multiparametric MRI (mpMRI), combined with PI-RADS scoring, has emerged as a valuable triage tool, potentially allowing clinicians to safely avoid biopsy in low-risk cases. Despite short-term data supporting this approach, medium- to long-term safety outcomes, including progression risk and treatment rates, remain incompletely understood. The RAPID MRI-directed prostate cancer diagnostic pathway aims to address this gap by integrating imaging-based risk stratification with targeted PSA monitoring.
Study Design
This single-centre prospective cohort study evaluated men discharged from the RAPID pathway between 2017 and 2023. Eligible participants had either nonsuspicious MRI (PI-RADS or Likert score 1–2, or score 3 with PSA density below 0.12 ng/ml²) and avoided biopsy, or had a negative biopsy despite suspicious MRI findings (PI-RADS 3 with high PSA density or PI-RADS 4–5). Follow-up included regular PSA monitoring and clinical review. The primary endpoints were grade group (GG) ≥2 cancer diagnosis-free survival (Dx-FS) and treatment-free survival (TFS). Secondary outcomes included GG ≥3 Dx-FS, GG 1 Dx-FS, biopsy-free survival (Bx-FS), cancer-specific survival, metastasis incidence, and re-referral rates. Data sources included a prospective registry and electronic clinical records, supplemented by direct patient contact for those without recent follow-up.
Key Findings
Of 2334 men evaluated through the RAPID pathway, 1266 met inclusion criteria for this analysis (927 avoided biopsy, 339 had negative biopsy). Median follow-up was 3.4 years (IQR 2.4–4.9 years). In total, 74 men developed GG ≥2 cancer, while seven developed GG 1 disease. The 5-year Dx-FS was 91.9% for GG ≥2 disease (95% CI 90.0–93.9%), and 96.3% for GG ≥3 disease (95% CI 95.0–97.7%). For GG 1 disease, Dx-FS reached 99.4% (95% CI 98.9–99.8%). The 5-year TFS rate was 94.4% (95% CI 92.6–95.9%).
Among those who initially avoided biopsy, the 5-year biopsy-free survival was 79.6% (95% CI 73.7–85.8%), meaning that 39% of the original pathway cohort remained biopsy-free after 5 years. Importantly, no patient developed metastatic disease or died from prostate cancer within the follow-up window. Variables such as higher PSA density, higher PI-RADS score, or atypical/histological findings (e.g., atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia) did not predict the eventual diagnosis of GG ≥2 disease.
Expert Commentary
These findings reinforce the safety and clinical validity of MRI-based triage in prostate cancer diagnostics over a medium-term horizon. The RAPID pathway’s reliance on combining PI-RADS scoring with PSA density measurements allows for accurate risk stratification and judicious biopsy avoidance. From a health systems perspective, this translates into reduced procedure-related morbidity, lower healthcare costs, and improved patient quality of life.
However, the single-centre setting limits generalizability. Further, 19% of potential data were excluded due to short follow-up, which may have introduced a selection bias. External validation in multicentre cohorts with longer surveillance would strengthen confidence in these results.
Conclusion
The RAPID MRI-directed prostate cancer diagnostic pathway safely avoids unnecessary biopsies without compromising long-term oncologic outcomes. At 5 years, only 1 in 13 discharged patients developed GG ≥2 cancer, and only 1 in 20 required treatment. Four in ten patients avoided biopsy entirely, with no metastatic or cancer-specific mortality detected. Clinically, these results support broader adoption of MRI-based triage algorithms, with continued monitoring and PSA-based surveillance for low-risk groups.
Funding and Registration
Study details are based on the published work by Ng CPY et al. in European Urology, 2025. No specific funding statements are provided within the summary. Clinical trial registration number not specified.
References
Ng CPY, Light A, Eragamreddy SK, Boaz RJ, Hunter A, Ashour O, Alderton D, Nicholls L, Hug O, Ang JZ, Raja A, Chua C, Hasan H, Wong F, Matthews M, Bhola-Stewart H, Adzawoloo-Andersson I, Mendoza R, Smith A, Lloyd J, Yeung M, Silvanto A, Mannion E, Lakhani A, Rockall A, Clark M, Tam H, Tanaka MB, Winkler M, Ahmed HU, Shah TT. Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway. Eur Urol. 2025 Nov 7:S0302-2838(25)04778-5. doi: 10.1016/j.eururo.2025.10.015. Epub ahead of print. PMID: 41206290.
Relevant guidelines: European Association of Urology (EAU) Prostate Cancer Guidelines, 2024 update; National Institute for Health and Care Excellence (NICE) prostate cancer recommendations.